Sparks - BioVersys

BioVersys has announced the peer-reviewed publication of two Phase I studies supporting the clinical pharmacology profile of BV100, its intravenous rifabutin formulation targeting carbapenem-resistant Acinetobacter baumannii (CRAB) infections. In 36 healthy volunteers, BV100 demonstrated strong lung penetration, achieving concentrations of around 35-fold higher in epithelial lining fluid and over 300-fold higher in alveolar macrophages than in plasma, supporting its potential in severe pneumonia. Separately, BV100 demonstrated relatively manageable drug interactions involving CYP3A, a key enzyme family responsible for metabolising many commonly prescribed medications. BV100 showed mild CYP3A induction, reducing midazolam exposure by 47%, while co-administration with the CYP3A inhibitor itraconazole increased rifabutin exposure by 1.3–1.7-fold. We view these observations positively, particularly given the multiple medications typically administered to critically ill patients.

The findings complement encouraging earlier Phase II efficacy signals, including lower 28-day mortality with BV100 versus best available therapy (28.5% versus 60%). We continue to view the pivotal Phase III RIV-TARGET readout, expected in early 2028, as the principal valuation catalyst, with interim Phase IIb RIV-CARE data anticipated in H127.